OncoCyte Corporation announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company's VitaGraft Kidney? diagnostic test, confirming that the test has met the criteria for coverage under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568). Launched via an early access program in Third Quarter 2022, the VitaGraft Kidney blood test is designed to identify signs of graft damage in patients with clinical suspicion of rejection at least 12 days post-transplant.

Kidney recipients represent the group of solid organ transplantations with almost 60% (~25,000) of all transplants done each year in the US and over 80% of the patients on the waiting list. VitaGraft Kidney is the first in a series of transplant tests in development at Oncocyte. VitaGraft Kidney addresses a $1B+ estimated kidney market that is part of a $2B+ estimated overall transplant market opportunity.